TY - JOUR
T1 - Distinct neurological disorders with ATP1A3 mutations.
AU - Heinzen, Erin L
AU - Gurrieri, Fiorella
AU - Arzimanoglou, Alexis
AU - Brashear, Allison
AU - Clapcote, Steven J
AU - Goldstein, David B
AU - Jóhannesson, Sigurdur H
AU - Mikati, Mohamad A
AU - Neville, Brian
AU - Nicole, Sophie
AU - Ozelius, Laurie J
AU - Poulsen, Hanne
AU - Schyns, Tsveta
AU - Sweadner, Kathleen J
AU - Van Den Maagdenberg, Arn
AU - Vilsen, Bente
PY - 2014
Y1 - 2014
N2 - Genetic research has shown that mutations that modify the protein-coding sequence of ATP1A3, the gene encoding the α3 subunit of Na+/K+-ATPase, cause both rapid-onset dystonia parkinsonism and alternating hemiplegia of childhood. These discoveries link two clinically distinct neurological diseases to the same gene, however, ATP1A3 mutations are, with one exception, disease-specific. Although the exact mechanism of how these mutations lead to disease is still unknown, much knowledge has been gained about functional consequences of ATP1A3 mutations using a range of in-vitro and animal model systems, and the role of Na+/K+-ATPases in the brain. Researchers and clinicians are attempting to further characterise neurological manifestations associated with mutations in ATP1A3, and to build on the existing molecular knowledge to understand how specific mutations can lead to different diseases.
AB - Genetic research has shown that mutations that modify the protein-coding sequence of ATP1A3, the gene encoding the α3 subunit of Na+/K+-ATPase, cause both rapid-onset dystonia parkinsonism and alternating hemiplegia of childhood. These discoveries link two clinically distinct neurological diseases to the same gene, however, ATP1A3 mutations are, with one exception, disease-specific. Although the exact mechanism of how these mutations lead to disease is still unknown, much knowledge has been gained about functional consequences of ATP1A3 mutations using a range of in-vitro and animal model systems, and the role of Na+/K+-ATPases in the brain. Researchers and clinicians are attempting to further characterise neurological manifestations associated with mutations in ATP1A3, and to build on the existing molecular knowledge to understand how specific mutations can lead to different diseases.
KW - ATP1A3, Alternating Hemiplegia Childhood
KW - ATP1A3, Alternating Hemiplegia Childhood
UR - http://hdl.handle.net/10807/56838
U2 - 10.1016/S1474-4422(14)70011-0
DO - 10.1016/S1474-4422(14)70011-0
M3 - Article
SN - 1474-4422
SP - 503
EP - 514
JO - LANCET NEUROLOGY
JF - LANCET NEUROLOGY
ER -